SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics (DFTX) is trending as investors react to a significant executive order accelerating research pathways for psychedelic-based therapies, which has bolstered confidence in the sector's regulatory outlook. The community is actively discussing the potential for institutional re-rating, strong cash reserves, and upcoming Phase 3 trial data, with many debating the company's status as a top buyout candidate.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crow with knife community is actively hyping the token as an essential meme-sector asset, emphasizing its deflationary burn mechanism and multichain presence. Supporters are rallying around the project's grassroots growth and organic cult following, often framing it as a lighthearted yet serious contender in the current meme coin landscape.

Highstreet

Highstreet is actively trending as the community debates its potential for a massive short squeeze following a period of extreme volatility and a sharp price decline. While some traders view the token as a high-conviction recovery play with an oversold chart, others express caution, labeling it a risky asset prone to repeated pump-and-dump cycles.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility as market participants debate whether the recent surge is driven by legitimate event-based utility or market manipulation. While supporters point to global festival partnerships and upcoming events as catalysts for growth, skeptics warn of concentrated token ownership and potential pump-and-dump mechanics amid heavy short-squeeze speculation.

PolySwarm

PolySwarm is capturing significant community attention as traders analyze the token's cybersecurity utility against a backdrop of ongoing accumulation and low-float volatility. Investors are actively discussing the potential for a breakout, citing technical setups, whale activity, and the increasing demand for decentralized threat detection as primary drivers.

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

Bright Minds Biosciences Inc

Bright Minds Biosciences is trending as investors frequently compare its potential to previous parabolic biotech runs, citing positive clinical data and strong analyst interest. The community remains focused on the possibility of a buyout or major partnership, often drawing parallels to past small-cap biotechs that saw dramatic, rapid appreciation.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is capturing significant community attention as traders debate its potential for a breakout, driven by speculation over future X platform integration and historical market cycles. While some investors are aggressively accumulating, others remain cautious, fueling an ongoing narrative war between those anticipating a major price rally and skeptics calling for a correction.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is seeing mixed community sentiment as investors weigh persistent concerns about token dilution against potential catalysts like upcoming exchange-linked ETF filings and ongoing integration with AI-focused infrastructure. While many retail holders express frustration over the asset's lagging performance compared to major tokens, others are actively accumulating, pointing to institutional interest and potential regulatory developments as reasons for long-term optimism.

Daddy Darth Sidious

SIDIOUS is gaining traction within the nano-cap meme coin community as traders speculate on a potential rotation from related tokens like MAULCOIN and DARTH. Participants are actively discussing entry points and the prospect of rapid growth, often framed around the concept of the 'Daddy Darth' thematic wars.

Daddy Darth Vader

Daddy Darth Vader ($DARTH) is trending as part of a highly debated "Daddy Wars" social media rivalry with other community-driven meme coins, fueled by aggressive token giveaways and community-led recruitment. Traders are actively discussing the project's low market cap, its potential as a weekend runner, and conflicting community opinions over whether the project acts as a legitimate trading vehicle or a high-risk pump and dump.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oak Harvest Investment Services Raises Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Oak Harvest Investment Services boosted its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 154.8% in the fourth quarter, according to the company in its most...

J&J Targets Double-Digit Growth by 2030 Despite Stelara Drag

J&J targets double-digit growth by 2030 despite Stelara hit, banking on Innovative Medicine strength, MedTech gains and new launches.

Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Greenwood Capital Associates LLC

Greenwood Capital Associates LLC lowered its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 12.9% in the fourth quarter, according to the company in its most recent...

Sumitomo Mitsui Trust Group Inc. Sells 469,305 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Sumitomo Mitsui Trust Group Inc. reduced its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 19.1% in the fourth quarter, according to its most recent disclosure with the...

J&J Beats Q1 Earnings & Sales Estimates, Raises 2026 Outlook

JNJ tops Q1 earnings and sales estimates, lifts 2026 outlook as strong oncology and MedTech growth offset steep Stelara decline.

AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook

Amneal Pharmaceuticals heads into 2026 with diversified growth drivers, rising margins and a faster launch cadence supporting steady revenue expansion.

Is AMRX Stock Undervalued? Sales Multiple, Target, Upside

Amneal Pharmaceuticals trades below peers on sales multiple despite strong gains, with a $14 target hinging on execution, mix shift, and margin strength.

Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing

Amneal Pharmaceuticals taps GLP-1 growth via a Pfizer-linked manufacturing deal, gaining exposure without clinical risks while scaling injectables and peptides.

Teva Pharmaceutical Industries (NYSE:TEVA) Given New $42.00 Price Target at Bank of America

Bank of America raised their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a "buy" rating in a research note on Thursday...

Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings?

JNJ approaches Q1 results with strong drug growth and MedTech momentum. However, rising biosimilar competition and pricing pressures cloud the outlook.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.47	--	--	N/A
Q4 '25	$0.64	$0.96	49.71%	BEAT
Q3 '25	$0.68	$0.78	15.54%	BEAT
Q2 '25	$0.62	$0.66	7.03%	BEAT
Q1 '25	$0.46	$0.52	12.43%	BEAT

TEVA
Teva- Pharmaceutical Industries Ltd. - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest TEVA News

TEVATeva- Pharmaceutical Industries Ltd. - ADR